Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.

Nature cell biology - 1 Nov 2016

Parrales Alejandro, Ranjan Atul, Iyer Swathi V, Padhye Subhash, Weir Scott J, Roy Anuradha, Iwakuma Tomoo

Abstract excerpt

Stabilization of mutant p53 (mutp53) in tumours greatly contributes to malignant progression. However, little is known about the underlying mechanisms and therapeutic approaches to destabilize mutp53. Here, through high-throughput screening we identify statins, cholesterol-lowering drugs, as degradation inducers for conformational or misfolded p53 mutants with minimal effects on wild-type p53 (wtp53) and DNA...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Movement
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HSP40 Heat-Shock Proteins

Share to Mevalonic Acid

Share to Protein Binding

Share to Tumor Suppressor Protein p53

Share to Ubiquitination

Source

Open in PubMed Open full text

Identifiers

PMID: 27775703
DOI: 10.1038/ncb3427
PMCID: PMC5340314

Genes

DNAJA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway.PMID 27775703Read ↗

The interplay between mutant p53 and the mevalonate pathway.Semantic proximity Read ↗

Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 MutationsSemantic proximity Read ↗

Recent Advances of Wee1 Inhibitors and Statins in Gynecologic Cancers with p53 MutationsSemantic proximity Read ↗

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions.Semantic proximity Read ↗

Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic TargetSemantic proximity Read ↗

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.Semantic proximity Read ↗

Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4Semantic proximity Read ↗

Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell deathSemantic proximity Read ↗

Suppression of HSF1 activity by wildtype p53 creates the driving force for p53 loss-of-heterozygosity, enabling mutant p53 stabilization and invasionSemantic proximity Read ↗

Mutations, protein homeostasis, and epigenetic control of genome integrity.Semantic proximity Read ↗

p53 mutations define the chromatin landscape to confer drug tolerance in pancreatic cancer.Semantic proximity Read ↗

Chaperones and Ubiquitin Ligases Balance Mutant p53 Protein Stability in Esophageal and Other Digestive Cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.